FDA Stacks 7-Peptide Review Panel With Industry Backers Favored by RFK Jr.
Updated
Updated · The Associated Press · Jun 29
FDA Stacks 7-Peptide Review Panel With Industry Backers Favored by RFK Jr.
3 articles · Updated · The Associated Press · Jun 29
Summary
More than a half-dozen July panelists released Monday run peptide clinics, pharmacies or online businesses, marking a sharp shift from earlier FDA advisory groups dominated by university researchers.
The two-day meeting will reconsider seven injectable peptides, including BPC-157 and TB-500, even though the FDA has repeatedly warned they are poorly studied and previous panels deemed similar ingredients too risky for patients.
Named members include Florida clinic operator Haleem Mohammed, influencer-doctor Gabriel Alizaidy and Tennessee pharmacist-state senator Bobby Harshbarger, whose family and political ties link him closely to the peptide industry.
The lineup fits Robert F. Kennedy Jr.'s broader remaking of federal health advice: he has praised peptides, replaced the CDC's 17-member vaccine panel and backed handpicked expert meetings over traditional advisory committees.